Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 7/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118975 | 0.85 | RXFP1 (0.51) | MPOCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2424537 | 0.81 | HTT (0.53) | MPOCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29487354 | 0.81 | HTT (0.53) | MPOCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29490199 | 0.78 | MPO (0.43) | MPORXFP1ACHEPDE10APOLB | |
| SCHEMBL17752895 | 0.78 | PTGES (0.41) | CYP1A2CYP2C19ACHENQO2PTGES | |
| SCHEMBL24373387 | 0.78 | MPO (0.46) | MPOCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL856384 | 0.78 | MPO (0.43) | MPORXFP1ACHEPDE10APOLB | |
| SCHEMBL7427955 | 0.78 | MPO (0.46) | MPOCYP1A2CYP2C19RXFP1ACHE | |
| SCHEMBL22234107 | 0.78 | HRH4 (0.50) | MPOACHEPTGESHTTHRH4 | |
| SCHEMBL15033544 | 0.77 | PRNP (0.50) | MPOCYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| US-20040029901-A1 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2004005265-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| CN-1444563-A | Quinoline and quinazoline derivatives | HOFFMANN LA ROCHE (CH) | 2003-09-24 | — | — | CN | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| EP-1318981-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | disclosed |
| WO-2002020488-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | MPO 141/4885CYP1A2 890/4885CYP2D6 711/4885 |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | MPO 3001/4885CYP1A2 399/4885CYP2D6 275/4885 |
| US-20040029901-A1 | Quinazoline derivatives | GPR119, NQO2, CYP7A1 | MPO 2241/4885CYP1A2 21/4885CYP2D6 95/4885 |
| US-20020052356-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | MPO 2731/4885CYP1A2 3834/4885CYP2D6 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.